[go: up one dir, main page]

WO2012026663A1 - Complément anticancéreux comprenant un acide undécylénique, un acide linoléique conjugué, et/ou un isomère de l'acide linoléique conjugué - Google Patents

Complément anticancéreux comprenant un acide undécylénique, un acide linoléique conjugué, et/ou un isomère de l'acide linoléique conjugué Download PDF

Info

Publication number
WO2012026663A1
WO2012026663A1 PCT/KR2011/002726 KR2011002726W WO2012026663A1 WO 2012026663 A1 WO2012026663 A1 WO 2012026663A1 KR 2011002726 W KR2011002726 W KR 2011002726W WO 2012026663 A1 WO2012026663 A1 WO 2012026663A1
Authority
WO
WIPO (PCT)
Prior art keywords
anticancer
cancer
conjugated linoleic
linoleic acid
taxol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2011/002726
Other languages
English (en)
Korean (ko)
Inventor
권영주
이은영
최용문
남태규
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ewha Womans University
Original Assignee
Ewha Womans University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020110030394A external-priority patent/KR101234985B1/ko
Application filed by Ewha Womans University filed Critical Ewha Womans University
Publication of WO2012026663A1 publication Critical patent/WO2012026663A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention is an anticancer adjuvant comprising at least one fatty acid selected from the group consisting of undecylene acid, conjugated linoleic acid and conjugated linoleic acid isomers as an active ingredient, a composition for inhibiting peripheral nervous system diseases caused by administration of an anticancer agent, and inhibiting or improving peripheral nervous system diseases.
  • Pharmaceutical compositions, quasi-drug compositions, and food compositions comprising the anticancer adjuvant It relates to a pharmaceutical composition for treating cancer and a method for treating cancer comprising the anticancer adjuvant and Taxol as an active ingredient.
  • Taxol is isolated and purified from Taxus brevifolia and is widely used in the treatment of breast and ovarian cancer. Taxol has an anticancer effect by regulating the cell cycle. It selectively acts on tubulin without affecting the synthesis of DNA and RNA of cancer cells and without damaging the DNA molecule itself. By preventing the depolymerization of the polymerized tubulin, cancer cell death is stopped by stopping the growth of cancer cells in the middle of cell division.
  • Taxol has the side effect of breaking down neurites of nerve cells and causing peripheral neuropathy.
  • Taxol decomposes neurites and breaks the homeostasis of signal transduction in the neuromuscular junction, calcium is continuously released from the mitochondria and calcium-dependent protease calpine is continuously activated.
  • p35 the substrate of calpein
  • p25 forms a complex with Cyclin-dependent kinase 5 (Cdk5) whose activity is regulated by p35.
  • Cdk5 Cyclin-dependent kinase 5
  • the p25 / Cdk5 complex pathologically sustains the phosphorylation activity of Cdk5, resulting in hyperphosphorylation of tau protein.
  • the superphosphorylated tau protein produces a neurofibrillary tangle (NFT), which acts as a pathogenesis of Alzheimer's disease (Patrick G. N et al., Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration, Nature 402, 615-622, 1999).
  • NFT neurofibrillary tangle
  • activated calpain activates caspase-3 and caspase-9, which play a key role in apoptosis.
  • Activation of calpine / casease-3 cleaves DNA, causing apoptosis of neurons.
  • calpine inhibitor that can not only inhibit the activity of calpine, but also reduce the side effects of anticancer agents including Taxol.
  • the present inventors have made intensive efforts to identify compounds having the activity of inhibiting calpine and simultaneously inducing the differentiation of neurites inhibited by anticancer agents.
  • undecylenic acid, conjugated linoleic acid or conjugated linoleic acid isomers are representative.
  • anti-cancer drug Taxol it was confirmed that differentiation of the neurites inhibited by Taxol was inhibited at the same time as the activity of calpine was suppressed, and the present invention was completed.
  • An object of the present invention is to provide an anticancer adjuvant comprising at least one fatty acid selected from the group consisting of undecylenic acid, conjugated linoleic acid and conjugated linoleic acid isomers.
  • Another object of the present invention to provide a pharmaceutical composition comprising the anticancer adjuvant.
  • Another object of the present invention is to provide a method for inhibiting or ameliorating peripheral nervous system diseases caused by an anticancer agent, comprising administering the pharmaceutical composition to a subject having a peripheral nervous system disease caused by an anticancer agent.
  • Still another object of the present invention is to provide a quasi-drug composition comprising the anticancer adjuvant.
  • Still another object of the present invention is to provide a food composition comprising the anticancer aid.
  • Another object of the present invention to provide a pharmaceutical composition for treating cancer comprising the anticancer adjuvant and Taxol as an active ingredient.
  • Still another object of the present invention is to provide a method for treating cancer, comprising administering the pharmaceutical composition for treating cancer to a subject having cancer.
  • Still another object of the present invention is to provide a cancer improving food composition comprising the anticancer aid and Taxol as an active ingredient.
  • Still another object of the present invention is to provide a composition for inhibiting peripheral nervous system disease caused by administration of an anticancer agent comprising at least one fatty acid selected from the group consisting of undecylenic acid, conjugated linoleic acid and conjugated linoleic acid isomers as an active ingredient.
  • the present invention provides an anticancer adjuvant comprising at least one fatty acid selected from the group consisting of undecylenic acid, conjugated linoleic acid and conjugated linoleic acid isomers.
  • conjugated linoleic acid is a derivative of undecylenic acid (UDA), which is a positional geometric isomer of linoleic acid, which is an essential fatty acid, and traces in the ruminant's milk or muscle. Means the natural fatty acid component found.
  • UDA undecylenic acid
  • the conjugated linoleic acid is composed of various isomers of linoleic acid having conjugated double bonds in cis or trans arrays of double bonds of octadecadienoic acid having 18 carbon atoms. isomers, and these conjugated linoleic acids may have cis or trans arrangements at positions 9 and 11 and 10 and 12, and theoretically by isomerization of linoleic acid (cis-9, cis-12 octadecadienoic acid). Sixteen structures and geometric isomers can be formed.
  • the conjugated linoleic acid isomer may be, but is not limited to, cis9, trans11-conjugated linoleic acid (cis9, trans11-CLA) or trans10, cis12-conjugated linoleic acid (trans10, cis12-CLA).
  • undecylenic acid, conjugated linoleic acid and conjugated linoleic acid isomers can be purchased and used commercially, or can be extracted and separated from castor ( Ricinus communis L. ).
  • cancer is a tumor or a tumor composed of undifferentiated cells that have unlimited proliferation in tissues
  • the anticancer adjuvant of the present invention can be used for any type of cancer that develops in each part of the body.
  • Can be used for the treatment of any one or more cancers selected from the group consisting of colorectal cancer, liver cancer, thyroid cancer, gallbladder cancer, biliary tract cancer, pancreatic cancer, prostate cancer, esophageal cancer, cervical cancer, colon cancer, bladder cancer, central nerve tumor and brain tumor Preferably it can be used for the treatment of any one or more cancers selected from the group consisting of ovarian cancer, breast cancer, lung cancer and gastric cancer.
  • the anticancer adjuvant of the present invention can be used to increase the anticancer effect of the anticancer agent and to suppress or improve the side effects of the anticancer agent.
  • the side effect of the anticancer agent may be a peripheral nervous system disease caused by the anticancer agent, more preferably in Taxol. Inhibition of neurites due to neurogenesis (neurogenesis) and thereby peripheral nervous system diseases.
  • undecylenic acid, conjugated linoleic acid or conjugated linoleic acid isomers not only inhibit the activity of ⁇ -calpain (Table 1), but also restore the inhibition of the differentiation of neurites, which is an anti-cancer side effect of Taxol. Excellent effect was shown (FIGS. 4-6). Therefore, undecylenic acid, conjugated linoleic acid or conjugated linoleic acid isomers can be usefully used for the treatment of cancer as an anticancer adjuvant, and can suppress or eliminate side effects caused by anticancer agents.
  • the anticancer adjuvant of the present invention may be administered in combination with any kind of anticancer agent or anticancer agent to increase the anticancer effect of the anticancer agent and to suppress or improve the side effects of the anticancer agent.
  • the anticancer adjuvant of the present invention may be administered in combination with Taxol or Taxotere.
  • the term “inhibition” means any action that reduces the side effects of an anticancer agent by the administration of an anticancer adjuvant
  • the term “improvement” in the present invention means the reduction of the side effects of an anticancer agent or the side effects of an anticancer agent by the administration of an anticancer adjuvant. It means any behavior that improves or beneficially changes the symptoms caused by cancer.
  • the term "individual" means all animals including humans who may develop or may develop cancer, and by administering the anticancer adjuvant of the present invention to a subject, cancer may be effectively treated while minimizing side effects of anticancer agents.
  • the anticancer adjuvant of the present invention can be administered to a human suffering from cancer, including breast cancer, which is being treated with an anticancer agent, thereby effectively treating the cancer while reducing side effects of the cancer.
  • the route of administration of the anticancer adjuvant may be administered through any general route as long as it can reach the target tissue.
  • the anticancer adjuvant of the present invention may be administered as intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, intranasal administration, intrapulmonary administration, rectal administration, but is not limited thereto. Does not.
  • the anticancer adjuvant may be administered by any device that allows the active substance to migrate to the target cell.
  • the present invention provides a pharmaceutical composition comprising an anticancer adjuvant according to the present invention.
  • the present invention provides a method for inhibiting or ameliorating peripheral nervous system diseases caused by an anticancer agent, comprising administering the pharmaceutical composition to a subject having a peripheral nervous system disease caused by an anticancer agent.
  • peripheral nervous system diseases caused by anticancer drugs may include not only peripheral nervous system diseases caused by side effects due to the administration of anticancer drugs, but also the peripheral nervous system diseases already developed may be exacerbated by the administration of anticancer drugs.
  • the term “inhibition” means any action of reducing the side effects of an anticancer agent, in particular, peripheral nervous system diseases caused by an anticancer agent by administration of a pharmaceutical composition comprising an anticancer adjuvant, and the term “improvement” in the present invention.
  • Anti-cancer side effects by administration of a pharmaceutical composition comprising an anticancer adjuvant means any action that improves or advantageously alters the symptoms caused by cancer due to a decrease or decrease in peripheral nervous system diseases caused by the anticancer agent.
  • the term "individual” means all animals including humans who may develop or may develop peripheral nervous system diseases caused by anticancer agents, and by administering to a subject a pharmaceutical composition comprising the anticancer adjuvant of the present invention, Anti-cancer side effects can effectively treat cancer, especially with minimal peripheral nervous system disease.
  • the anticancer agent may be Taxol
  • the peripheral nervous system disease may be peripheral neuropathy.
  • compositions of the present invention may include a pharmaceutically acceptable carrier.
  • Compositions of the present invention comprising a pharmaceutically acceptable carrier may be in various oral or parenteral formulations.
  • diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used.
  • Solid form preparations for oral administration include tablet pills, powders, granules, capsules, and the like, which form at least one excipient such as starch, calcium carbonate, sucrose or lactose in one or more compounds. ) And gelatin.
  • lubricants such as magnesium stearate, talc and the like are also used.
  • Liquid preparations for oral administration include suspensions, solution solutions, emulsions, and syrups, and various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin, may be included.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
  • non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used.
  • As the base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • the pharmaceutical composition of the present invention is selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, liquid solutions, emulsions, syrups, sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations and suppositories It can have any one formulation.
  • the pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount.
  • pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level is determined by the type of subject and its severity, age, sex, activity of the drug, drug. Sensitivity, time of administration, route of administration and rate of excretion, duration of treatment, type of cancer, consideration of concurrent anticancer agents, and other factors well known in the medical arts.
  • the pharmaceutical composition of the present invention is oral or parenteral route once or twice daily in an amount of 0.001 to 100 mg / kg body weight, preferably 0.01 to 50 mg / kg. It can be administered through.
  • the pharmaceutical composition of the present invention may be administered sequentially or simultaneously with anticancer agents known in the art, and may be administered single or multiple. In consideration of all the above factors, it is important to administer an amount that can obtain the maximum effect with a minimum amount without side effects, and may be usually determined by the prescribing doctor.
  • composition of the present invention can be used in combination with methods using surgery, hormonal therapy, drug therapy and biological response modifiers for anticancer therapy.
  • the present invention provides a quasi-drug composition comprising an anticancer adjuvant according to the present invention. More specifically, the composition of the present invention can be added to the quasi-drug composition for the purpose of suppressing or improving side effects due to the administration of anticancer drugs.
  • the anticancer adjuvant of the present invention when used as an quasi-drug additive, the anti-cancer adjuvant may be added as it is or used with other quasi-drugs or quasi-drug components, and may be appropriately used according to a conventional method.
  • the mixing amount of the active ingredient may be appropriately determined depending on the intended use.
  • the quasi-drug composition of the present invention may be a disinfectant cleaner, a shower foam, a Gagreen, a wet tissue, a detergent soap, a hand wash, a humidifier filler, a mask, an ointment or a filter filler.
  • the present invention provides a food composition comprising an anticancer adjuvant according to the present invention. More specifically, the anticancer adjuvant of the present invention may be added to the food composition for the purpose of suppressing or improving the side effects caused by the administration of the anticancer agent.
  • the food composition of the present invention corresponds to all forms of health functional foods, nutritional supplements, nutritional supplements, pharmafood, health food, nutraceutical, designer food, food additives and the like.
  • the fatty acid may be added as it is or used with other food or food ingredients, and may be appropriately used according to a conventional method.
  • the mixed amount of the active ingredient may be appropriately determined depending on the stage of cancer progression, the type of cancer, the type of anticancer agent administered in combination, and the like.
  • Examples of the food to which the substance can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, drinks, Alcoholic beverages and vitamin complexes, and the like, may include all of the health food in the conventional sense.
  • the food composition of the present invention includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols. And carbonation agents used in carbonated beverages.
  • the food composition of the present invention may contain a flesh for preparing natural fruit juice, fruit juice beverage and vegetable beverage.
  • the present invention provides a pharmaceutical composition for treating cancer comprising the anticancer adjuvant and Taxol according to the present invention as an active ingredient.
  • the pharmaceutical composition for treating cancer according to the present invention can be used.
  • the present invention provides a method for treating cancer, comprising administering a pharmaceutical composition for treating cancer according to the present invention to a subject having cancer.
  • treatment refers to any action that improves or advantageously changes the symptoms caused by cancer by administration of the pharmaceutical composition for treating cancer of the present invention.
  • the cancer may be any one or more cancers selected from the group consisting of ovarian cancer, breast cancer, stomach cancer, and lung cancer.
  • the mixing ratio of the anticancer adjuvant and Taxol is well known in the type of cancer, the age of the patient, the extent of cancer, the site of the cancer, the sex of the patient, the history of the patient and the amount of Taxol to be administered and other medical fields It can be determined according to the factors, but can usually be determined by the prescriber.
  • the pharmaceutical composition for treating cancer of the present invention may include a pharmaceutically acceptable carrier, as described above.
  • the present invention provides a cancer improving food composition
  • a cancer improving food composition comprising an anticancer adjuvant and Taxol according to the present invention as an active ingredient.
  • cancer improving food composition of the present invention are as described in the food composition comprising an anticancer adjuvant.
  • the present invention provides a composition for inhibiting peripheral nervous system diseases caused by administration of an anticancer agent comprising at least one fatty acid selected from the group consisting of undecylene acid, conjugated linoleic acid and conjugated linoleic acid isomers as an active ingredient.
  • peripheral nervous system disease caused by anticancer drug administration may include not only peripheral nervous system disease caused by side effects due to anticancer drug administration, but also a peripheral nervous system disease that has already developed may be exacerbated by anticancer drug administration.
  • composition for inhibiting peripheral nervous system diseases of the present invention can be used to suppress peripheral nervous system diseases caused by administration of anticancer agents, and preferably, to suppress peripheral nervous system diseases that can be caused by inhibition of neurogenesis differentiation by Taxol. Can be used.
  • Undecylenic acid, conjugated linoleic acid or conjugated linoleic acid isomers exhibit the effect of restoring the differentiation inhibition (neurogenesis) of neurites by Taxol (Figs. 4 to 6), so that the composition for inhibiting peripheral nervous system diseases of the present invention is Taxol and By co-administration together, it can be useful for preventing or treating peripheral nervous system diseases caused by Taxol.
  • peripheral nervous system diseases include all diseases caused by inhibiting the differentiation of neurites due to the administration of an anticancer agent, for example, peripheral neuropathy, diabetic peripheral neuropathy, neuromyopathy and autoimmune peripheral neuropathy. It is not limited.
  • the anticancer adjuvant comprising at least one fatty acid selected from the group consisting of undecylenic acid, conjugated linoleic acid and conjugated linoleic acid isomers according to the present invention as an active ingredient enhances the anticancer effect of the anticancer agent and at the same time inhibits the anticancer side effects. It can be useful for the treatment of
  • 1 is a diagram showing the neuronal differentiation process of P19 cells of teratoma.
  • A is a schematic diagram of the neuronal differentiation experiment of P19 cell by NeuroD2.
  • FIG. 1B is a bright field image obtained by Differential Interference Contrast Microscope after transfecting NeuroD2 in a P19 cell line and incubating for 4 days, followed by immunostaining of beta III tubulin. Indicates.
  • 1C is a fluorescence image of cells in which NeuroD2 is delivered expressing beta III tubulin.
  • Figure 2 is a photograph showing the neurites of P19 cells differentiated into neurons.
  • Neuronal Profiling Bioapplication algorithm shows green and purple color along the length of neurites, and blue indicates cell body.
  • Figure 3 is a photograph showing that the differentiation of neurites was inhibited by the concentration-specific treatment of Taxol.
  • 5 is a photograph showing that differentiation of neurites suppressed by Taxol occurred when undecylenic acid, conjugated linoleic acid or conjugated linoleic acid isomers were treated with Taxol 25 nM.
  • CLA 9Z11E and CLA 10E12Z in FIGS. 4-5 represent cis9, trans11-CLA and trans10, cis12-CLA, respectively.
  • Fluorescence assays were performed in 96-well plates, and the end-point fluorescence intensity of each well was measured using a Microplate Fluorescence Reader (SPECREAmax GEMINI EM , Molecular Divices). IC 50 was measured by data graphing software TableCurve 2D (Systat software Inc.). Fluorescence intensity was expressed in RFU (Relative fluorescence unit).
  • pep2 ⁇ -calcane cleaves between phenylalanine and alanine in pep2.
  • the assay uses a reaction buffer (50 mM Tris-HCl, 50 mM NaCl, 1 mM EDTA, 5 mM ⁇ -mercaptoethanol; pH 7.5) at a final volume of 100 ⁇ l, 100 ⁇ M pep2, 2.5 mM CaCl 2 , 5.25 units / ml Calpine (Calbiochem, Germany) purified from human erythrocytes was used.
  • Substrate, ⁇ -calpein, and the compound to be tested are added in order, and finally, CaCl 2 is added, followed by incubation at room temperature for 30 minutes, followed by fluorescence intensity at 320 nm excitation (ex) and 420 nm emission (em). The change was measured.
  • MDL28170 Sigma, USA
  • a calpine inhibitor As a positive control, MDL28170 (sigma, USA), which is known as a calpine inhibitor, was used.
  • Cat-B reaction buffer [50 mM sodium acetate, 2 mM dithiothreitol (DTT), 2 mM ethylenediaminetetraacetic acid (EDTA); pH 5.5] and a 20 ⁇ M substrate, 1.5 nM Cat-B (Calbiochem, Germany), 4 nM Cat-L (Calbiochem, using a Cat-L reaction buffer (200 mM sodium acetate, 4 mM EDTA, 8 mM DTT; pH 5.5)). Germany).
  • Substrates were Z-RR-AMC, a Cat-B specific substrate, and Z-FR-AMC, a Cat-L substrate.
  • Kadepsin (Cathepsin) was previously reacted for 30 minutes at 37 ° C.
  • lauric acid inhibited Cat-B activity by about 60% at 100 ⁇ M
  • arachidonic acid was concentration-independent at 100 ⁇ M. 98% inhibition of Cat-B activity.
  • Gamma-linoleic acid had no calpine inhibitory effect, but inhibited Cat-B and Cat-L activity at IC 50 values of 8.08 ⁇ M and 3.78 ⁇ M, respectively. Since the substrate contained a cleavage site of p35, it was found that these compounds inhibited the calpein overactivation resulting in cleavage of p35 to p25.
  • conjugated linoleic acid and conjugated linoleic acid isomers having ⁇ -calcine inhibitory activity can restore differentiation of neurites inhibited by Taxol, Was performed.
  • P19 cells an embryonic carcinoma
  • DMEM Hyclone laboratories Inc, USA
  • FBS Hyclone laboratories Inc, USA
  • penicillin 1% penicillin.
  • Cells were maintained at 37 ° C., 5% CO 2 environment. The medium was changed every two to three days, and the subculture was 1: 4 to 1: 8.
  • neuroD2 a neuronal transcription factor, was transfected and cultured for 4 days.
  • beta III tubulin beta III tubulin specifically expressing only neurons (Neuron) was immunostained to measure the degree of differentiation of neurons (see FIG. 1).
  • P19 cells differentiated into neurons were treated with Taxol, Undecylenic Acid (UDA), Conjugated Linoleic Acid (CLA), Conjugated Linoleic Acid Isomer, or DMSO (Control), and images were acquired using Cellmics, an image analyzer. Then, the length (differentiation degree) of the neurites was measured by a Neuronal Profiling Bioapplication algorithm. At this time, it is divided into green or purple according to the length of the neurites, and numerical results can be obtained (see FIG. 2).
  • UDA Undecylenic Acid
  • CLA Conjugated Linoleic Acid
  • DMSO Conjugated Linoleic Acid Isomer
  • Example 2-1 the result of treating Taxol to P19 cells by concentration is shown in FIG. 3.
  • the differentiation of neurites was suppressed in the Taxol treatment group compared to the DMSO treatment group as a control group, and it was confirmed that the differentiation of the neurites was remarkably suppressed especially when the Taxol treatment was 10 nM or more (see FIG. 3).
  • Example 2-1 the result of treatment of Taxol 10 nM and undecylenic acid, conjugated linoleic acid or conjugated linoleic acid isomers (9Z11E, 10E12Z) with 10 ⁇ M or 20 ⁇ M, respectively, was carried out according to the experimental method of Example 2-1. .
  • 10 ⁇ M or 20 ⁇ M of undecylenic acid, conjugated linoleic acid or conjugated linoleic acid isomers were treated, it was confirmed that differentiation of neurites suppressed by Taxol occurred.
  • 9Z11E it was confirmed that differentiation of neurites inhibited by Taxol occurred remarkably (see FIG. 4).
  • Example 2-1 P19 cells were treated with Taxol 25 nM, undecylenic acid, conjugated linoleic acid or conjugated linoleic acid isomers (9Z11E, 10E12Z) at 10 ⁇ M or 20 ⁇ M, respectively. .
  • 10 ⁇ M or 20 ⁇ M of undecylenic acid, conjugated linoleic acid or conjugated linoleic acid isomers were treated, it was confirmed that differentiation of neurites suppressed by Taxol occurred.
  • 9Z11E it was confirmed that differentiation of neurites suppressed by Taxol occurred remarkably (see FIG. 5).

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un complément anticancéreux comprenant au moins un acide gras choisi dans le groupe constitué par l'acide undécylénique, l'acide linoléique conjugué, et un isomère d'acide linoléique conjugué comme principe actif, une composition permettant d'inhiber les troubles du système nerveux périphérique induits par l'administration d'agents anticancéreux, et un procédé permettant d'inhiber ou d'améliorer les troubles du système nerveux périphérique, ainsi que des compositions pharmacologiques, non médicinales et alimentaires qui comprennent le supplément anticancéreux. L'invention concerne en outre une composition pharmacologique comprenant le complément anticancéreux et du taxol comme principes actifs aux fins de traitement anticancéreux et un procédé pour le traitement du cancer, qui peuvent être utilisés efficacement aux fins de traiter le cancer en augmentant les effets de l'activité anticancéreuse et en éliminant les effets secondaires des agents anticancéreux.
PCT/KR2011/002726 2010-08-25 2011-04-15 Complément anticancéreux comprenant un acide undécylénique, un acide linoléique conjugué, et/ou un isomère de l'acide linoléique conjugué Ceased WO2012026663A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20100082690 2010-08-25
KR10-2010-0082690 2010-08-25
KR1020110030394A KR101234985B1 (ko) 2010-08-25 2011-04-01 운데실렌산, 공액리놀레산 및/또는 공액리놀레산 이성질체를 포함하는 항암보조제
KR10-2011-0030394 2011-04-01

Publications (1)

Publication Number Publication Date
WO2012026663A1 true WO2012026663A1 (fr) 2012-03-01

Family

ID=45723637

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/002726 Ceased WO2012026663A1 (fr) 2010-08-25 2011-04-15 Complément anticancéreux comprenant un acide undécylénique, un acide linoléique conjugué, et/ou un isomère de l'acide linoléique conjugué

Country Status (1)

Country Link
WO (1) WO2012026663A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2900270B1 (fr) * 2012-09-26 2019-03-06 Tangent Reprofiling Limited Combinaison des benzo (iso)oxazolepiperidines avec un acide linoleique conjugué

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040099381A (ko) * 2002-03-27 2004-11-26 발리오 리미티드 공액 리놀레산의 제조 방법
KR100655838B1 (ko) * 1998-05-04 2006-12-12 콘린코 인크. 이성질체가 강화된 공액 리놀레산 조성물
KR100740564B1 (ko) * 2003-11-28 2007-07-18 주식회사 온바이오 공액화 리놀레산의 디글리세리드가 풍부한 유지조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100655838B1 (ko) * 1998-05-04 2006-12-12 콘린코 인크. 이성질체가 강화된 공액 리놀레산 조성물
KR20040099381A (ko) * 2002-03-27 2004-11-26 발리오 리미티드 공액 리놀레산의 제조 방법
KR100740564B1 (ko) * 2003-11-28 2007-07-18 주식회사 온바이오 공액화 리놀레산의 디글리세리드가 풍부한 유지조성물

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2900270B1 (fr) * 2012-09-26 2019-03-06 Tangent Reprofiling Limited Combinaison des benzo (iso)oxazolepiperidines avec un acide linoleique conjugué

Similar Documents

Publication Publication Date Title
Wei et al. Prenylflavonoids sanggenon C and kuwanon G from mulberry (Morus alba L.) as potent broad-spectrum bacterial β-glucuronidase inhibitors: Biological evaluation and molecular docking studies
WO2023038350A1 (fr) Composition pour soulager le syndrome prémenstruel, contenant des souches de lactobacillus mélangées en tant que principe actif
WO2018117659A1 (fr) Composition pharmaceutique comprenant un extrait de levis pulverata indigo ou une fraction de celui-ci comme principe actif pour prévenir ou traiter une maladie intestinale inflammatoire
WO2012078004A2 (fr) Composition contenant des extraits de thé fermenté et destinée à faire baisser le taux de lipides
JP2015096494A (ja) 生体内酸化還元状態改善剤
WO2019098811A2 (fr) Composition pour prévenir, soulager ou traiter des maladies de perte osseuse, comprenant cyclo(his-pro) (chp)
KR20120019785A (ko) Ｌｒｒｋ２ 인산화효소 억제 활성을 갖는 화합물을 유효성분으로 함유하는 파킨슨병 치료 또는 예방용 약학조성물
WO2011065791A2 (fr) Composition d'accélération de métabolisme comprenant un extrait de racine d'astragalus membranaceus
WO2020149636A1 (fr) Composition pharmaceutique contenant de l'aucubine et permettant de prévenir ou traiter le syndrome de l'oeil sec
WO2014098512A1 (fr) Composition pharmaceutique comprenant du fucostérol en tant que principe actif pour prévenir ou traiter des maladies neurodégénératives
CN117599027A (zh) 包含作为活性成分的蕨素化合物及其衍生物的组合物，用于预防或治疗退行性脑疾病
WO2020101181A1 (fr) Composition comprenant un aptamère en tant que principe actif pour le traitement et la prévention d'une maladie dégénérative du cerveau
WO2017026641A1 (fr) Composition destinée à prévenir ou traiter le cancer du col de l'utérus et contenant du gypenoside lxxv
WO2012026663A1 (fr) Complément anticancéreux comprenant un acide undécylénique, un acide linoléique conjugué, et/ou un isomère de l'acide linoléique conjugué
WO2011008052A2 (fr) Composition pour la prévention ou le traitement de maladies osseuses comprenant du daropate de colforsine
WO2020040382A1 (fr) Nouveau composé de magnésium-sérinate et son utilisation
WO2021107585A1 (fr) Composition pour améliorer la fonction cognitive, la mémoire et l'activité, comprenant un mélange d'extrait de schisandra chinensis et d'acide ascorbique en tant que principe actif
WO2025023787A1 (fr) Composition pour la prévention, l'amélioration ou le traitement de la dépression comprenant une souche de lactobacillus buchneri 200793
EP2902388B1 (fr) Produit de condensation de dérivé théanine et de dérivé coumarine d'acide carboxylique, intermédiaire du produit de condensation, leur procédé de préparation, et leur utilisation
KR101821498B1 (ko) 브루소찰콘 a를 유효성분으로 함유하는 암질환 예방 또는 치료용 약학조성물
KR101234985B1 (ko) 운데실렌산, 공액리놀레산 및/또는 공액리놀레산 이성질체를 포함하는 항암보조제
WO2016093613A2 (fr) Composition pour la prévention ou le traitement d'une perte de poids anormale, contenant un extrait de pelure de mandarine satsuma
WO2012026662A1 (fr) Composition comprenant un acide undécylénique et/ou un acide linoléique conjugué pour la prévention et le traitement de troubles neurologiques dégénératifs
WO2019098674A1 (fr) Composition pour la prévention ou le traitement de maladies neuropsychologiques contenant de l'aucubine
WO2022186608A1 (fr) Utilisation anticancéreuse d'extrait de gonades de stichopus japonicus ou de composés dérivés de celles-ci

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11820091

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11820091

Country of ref document: EP

Kind code of ref document: A1